Depression: all studies (page 185) - The Consciousness Library

Esketamine for treatment‑resistant depression: A review of clinical evidence (Review).

Experimental and therapeutic medicine March 2023 Octavian Vasiliu

Treatment-resistant depression (TRD) is a challenge for psychiatrists, even after more than seven decades since the first antidepressants were used in clinical practice. Non-monoaminergic-based drugs with antidepressant properties have been developed, but to date, only esketamine and brexanolone have been approved for TRD and postpartum depression, respectively. A narrative review on the...

DOI: 10.3892/etm.2023.11810 Full text Esketamine Major depressive disorder Treatment-resistant depression Psychotic depression +1

Esketamine nasal spray shows higher remission and response rates over 32 weeks of treatment compared with quetiapine extended-release in patients with treatment resistant depression: Results from ESCAPE-TRD, a randomised, phase IIIb clinical trial

PubMed Central March 1, 2023

INTRODUCTION: Treatment resistant depression (TRD) is estimated to affect 10–30% of patients with major depressive disorder (Al‑Harbi et al. Patient Prefer Adherence 2012; 6 369–88). Esketamine nasal spray (NS), in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrine reuptake inhibitor (SNRI), increases remission and response rates in patients with TRD...

DOI: 10.1192/j.eurpsy.2023.272 Full text

A Pilot Study of Telehealth Mindfulness-Based Cognitive Therapy for Depression in Parkinson's Disease.

Journal of geriatric psychiatry and neurology March 2023 Alejandro Interian, Rachael B Miller, Lauren M St Hill et al.

Introduction: Parkinson's disease (PD) is characterized by high-rates of depression with limited evidence-based treatment options to improve mood. Objective: To expand therapeutic options, we evaluated the feasibility and effect of a telehealth mindfulness-based cognitive therapy intervention adapted for PD (MBCT-PD) in a sample of participants with DSM-5 depressive disorders. Methods: Fifteen...

DOI: 10.1177/08919887221103579 Full text Depression Parkinson's disease Mindfulness meditation Psychotherapy +1

Effects of meditation on pain intensity, physical function, quality of life and depression in adults with low back pain - A systematic review with meta-analysis.

Complementary Therapies in Medicine March 1, 2023 Helena Schmidt, Christian Pilat

Low back pain (LBP) is a common biopsychosocial health problem. Meditation may provide a complementary treatment option for LBP patients. The aim of this systematic review with meta-analysis was to examine the effects of meditation on pain intensity, functional disability, quality of life, and depression in LBP populations. This systematic review was conducted according to the PRISMA...

DOI: 10.1016/j.ctim.2023.102924 Full text Meditation Mindfulness Chronic pain Low back pain +1

Improvement of depressive symptoms, after a suicide attempt, with dextromethorphan/bupropion combination treatment in a patient with treatment-resistant depression and psychiatric comorbidities.

Clinical Case Reports March 1, 2023 Bruno Pedraz-Petrozzi, Michael Deuschle, Maria Gilles

We admitted a 42-year-old patient with severe treatment-resistant depression and with psychiatric comorbidities. The patient attempted suicide 5 weeks after admission. Subsequently, we initiated dextromethorphan/bupropion based on prior evidence. As a result, the patient demonstrated an improvement in mood symptoms and a reduction in suicide risk, leading to her discharge.

DOI: 10.1002/ccr3.7045 Full text Depression Bupropion Comorbidity Dextromethorphan +1

Efficacy and adverse effects of ketamine versus electroconvulsive therapy for major depressive disorder: A systematic review and meta-analysis

Journal of Affective Disorders March 1, 2023 Debora de A. Simoes Moreira, Luís Eduardo Gauer, Guilherme Teixeira et al. 25 citations

Background: ECT is considered the fastest and most effective treatment for TRD. Ketamine seems to be an attractive alternative due to its rapid-onset antidepressant effects and impact on suicidal thoughts. This study aimed to compare efficacy and tolerability of ECT and ketamine for different depression outcomes (PROSPERO/CRD42022349220). Methods: We searched MEDLINE, Web of Science, Embase,...

DOI: 10.1016/j.jad.2023.02.152 Full text

Psychedelics for depression: from neurobiology to treatment

European Psychiatry March 1, 2023 K. P. Kuypers 2 citations

Abstract Decades ago, the classical psychedelics psilocybin and LSD entered the therapeutic setting and already then showed their therapeutic potential in the treatment of psychiatric disorders. For thousands of years another psychedelic, ayahuasca, is being used by tribes in western Amazonia for healing and divination, and in recent years its use has expanded worldwide. Research into the...

DOI: 10.1192/j.eurpsy.2023.74 Full text Psilocybin Psychotherapist Therapeutic effect Therapeutic approach +3

The therapeutic potential of psilocybin in depression resistant to psychotropic drugs

European Psychiatry March 1, 2023 J. Ramírez González, I. Fernández Márquez, Serafín González et al.

Introduction The use of hallucinogens has accompanied the human being throughout history. In the 1970s, studies focused on the therapeutic potential of hallucinogens were blocked due to their misuse in the young population. At present, psilocybin is re-emerging as the center of attention due to its possible therapeutic potential in different psychiatric pathologies such as depression, anxiety...

DOI: 10.1192/j.eurpsy.2023.1767 Full text Psilocybin Anxiety Major depressive disorder Hallucinogen +4

Improvement in Depression Symptoms Measured by Montgomery-Åsberg Depression Rating Scale and Quick Inventory of Depressive Symptomatology-Self Rated Items after Randomised Double-blind COMP360 Psilocybin Therapy for Treatment-resistant Depression

European Psychiatry March 1, 2023 Guy M. Goodwin, Lindsey Marwood, Sunil Mistry et al. 1 citation

Introduction COMP360 is a synthetic, proprietary, purified form of psilocybin in development for treatment-resistant depression (TRD) with FDA Breakthrough Therapy designation. In a recent phase IIb study, COMP360 psilocybin 25mg was superior to 1mg on change from baseline (CFB) to Week 3 on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score (primary efficacy endpoint), when...

DOI: 10.1192/j.eurpsy.2023.273 Full text Psilocybin Depression economics Rating scale Sadness +5

A Single Administration of Psilocybin Persistently Rescues Cognitive Deficits Caused by Adolescent Chronic Restraint Stress Without Long-Term Changes in Synaptic Protein Gene Expression in a Rat Experimental System with Translational Relevance to Depression.

Psychedelic Medicine March 1, 2023 Meghan Hibicke, Hannah M. Kramer, Charles D. Nichols 25 citations

Psilocybin has shown long-lasting antidepressant effects in preclinical and clinical trials, but the mechanisms responsible are unclear. As both passive coping strategies and pattern separation deficits are characteristics of major depression, we used adult female rats subjected to adolescent chronic restraint stress (aCRS) to investigate the effects of psilocybin on forced swim test (FST) and...

DOI: 10.1089/psymed.2022.0012 Full text Depression Psilocybin Adolescent stress Pattern separation +8